This product is for scientific research only. It is a +99% pure lyophilized pharmacy grade powder in a sealed, sterile vial, with the total weight indicated on the label. Product appearance, label, seal, and cap colors may vary slightly from the images shown. Additional supplies are required.
Peptides | GIP | GLP-1 | GCGR
Peptides | GIP | GLP-1 | GCGR
Rice Raw Pulp 6 x 50mg Lyophilised Powder & 6 x 3mL Lysosomal Solution
Peptides | GIP | GLP-1 | GCGR
![Cagrilintide is a long-acting acylated analogue of the metabolite GLP-1(7-36) amide that acts as a glucagon-like peptide-1 receptor (GLP-1R) agonist. It is being investigated for the treatment of type 2 diabetes mellitus and obesity.[1] Cagrilintide is a GLP-1 receptor agonist, meaning it mimics the effects of the incretin hormone GLP-1 which stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety.[2] As a result, cagrilintide can help lower blood glucose levels and promote weight loss in patients with type 2 diabetes and obesity. Cagrilintide: - GLP-1 receptor agonist for type 2 diabetes and obesity - Long-acting acylated analogue of GLP-1(7-36) amide - Stimulates insulin secretion and suppresses glucagon - Slows gastric emptying and increases satiety - Administered by subcutaneous injection - Currently in clinical trials for efficacy and safety evaluation[1][2] Citations: [1] https://www.novoprolabs.com/p/retatrutide-ly3437943--319206.html [2] https://en.wikipedia.org/wiki/Retatrutide [3] https://pubmed.ncbi.nlm.nih.gov/37385280/ [4] https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 [5] https://www.drugs.com/history/retatrutide.html](https://researchroi.com/wp-content/uploads/2024/05/Cagrilintide.jpg "Cagrilintide")
![Cagrilintide is a long-acting acylated analogue of the metabolite GLP-1(7-36) amide that acts as a glucagon-like peptide-1 receptor (GLP-1R) agonist. It is being investigated for the treatment of type 2 diabetes mellitus and obesity.[1] Cagrilintide is a GLP-1 receptor agonist, meaning it mimics the effects of the incretin hormone GLP-1 which stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety.[2] As a result, cagrilintide can help lower blood glucose levels and promote weight loss in patients with type 2 diabetes and obesity. Cagrilintide: - GLP-1 receptor agonist for type 2 diabetes and obesity - Long-acting acylated analogue of GLP-1(7-36) amide - Stimulates insulin secretion and suppresses glucagon - Slows gastric emptying and increases satiety - Administered by subcutaneous injection - Currently in clinical trials for efficacy and safety evaluation[1][2] Citations: [1] https://www.novoprolabs.com/p/retatrutide-ly3437943--319206.html [2] https://en.wikipedia.org/wiki/Retatrutide [3] https://pubmed.ncbi.nlm.nih.gov/37385280/ [4] https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 [5] https://www.drugs.com/history/retatrutide.html](https://researchroi.com/wp-content/uploads/2024/05/Cagrilintide-450x450.jpg)
